Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $89,942.86 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,847 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $23.38, for a total value of $89,942.86. Following the completion of the sale, the insider owned 121,338 shares in the company, valued at approximately $2,836,882.44. This represents a 3.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Stock Performance

NRIX stock traded down $0.02 during midday trading on Thursday, hitting $23.58. 1,248,824 shares of the stock were exchanged, compared to its average volume of 1,517,187. The stock’s 50-day moving average price is $20.31 and its 200-day moving average price is $17.78. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -6.83 and a beta of 1.80. Nurix Therapeutics, Inc. has a fifty-two week low of $8.19 and a fifty-two week high of $25.08.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.82 EPS for the current year.

Analyst Upgrades and Downgrades

NRIX has been the subject of a number of research reports. Mizuho lifted their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wells Fargo & Company lowered shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price target for the company from $28.00 to $25.00 in a research report on Monday, June 8th. BTIG Research reissued a “buy” rating and set a $32.00 price objective on shares of Nurix Therapeutics in a research note on Friday, July 10th. Truist Financial lifted their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research note on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.00.

Hedge Funds Weigh In On Nurix Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Larson Financial Group LLC grew its stake in Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after acquiring an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Nurix Therapeutics during the fourth quarter worth $33,000. KBC Group NV acquired a new stake in shares of Nurix Therapeutics during the first quarter worth $34,000. Finally, Wexford Capital LP purchased a new stake in shares of Nurix Therapeutics in the third quarter valued at $41,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.